Arno Therapeutics, Inc. (OTCQB: ARNI) is a clinical stage biopharmaceutical company developing innovative products for the treatment of cancer and other life threatening diseases. The company has exclusive worldwide rights to develop and market three innovative product candidates – including Onapristone, AR-42 and AR-12. These compounds are currently in clinical or preclinical development as product candidates to treat solid tumor and hematologic malignancies, as well as infectious diseases. For more information, visit the company’s website at www.arnothera.com.
Arno Therapeutics (ARNI) Presents at Rodman & Renshaw Conference
Previous Article
Next Article
Search Articles
Latest Articles
- MissionIRNewsBreaks – Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Marks Pivotal Moment on Path to 2026 Rare Earth Oxide Production
- PowerBank Corporation (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: 103) Marks Bold Entry Into the Growing Battery Storage Market with 4.99 MW BESS in Ontario
- Soligenix Inc. (NASDAQ: SNGX) Working to Advance Heat-Stable Ricin Vaccine with Promising Efficacy
- New Pacific Metals Corp. (NYSE American: NEWP) (TSX: NUAG) Eyes Bolivia’s Untapped Silver Potential Amid Global Supply Gaps
- MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Q2 2025 Results, Advances TPI 287 Toward Phase 2 GBM Trial